Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Essential thrombocythaemia.

Claire N Harrison1, Anthony R Green

  • 1Department of Haematology, Guy's and St Thomas, NHS Foundation Trust, Lanbeth Palace Road, London SE1 7EH, UK.

Best Practice & Research. Clinical Haematology
|June 20, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment.

HemaSphere·2026
Same author

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

British journal of haematology·2026
Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026
Same author

Genomic evolution and natural history of myeloproliferative neoplasms on therapy.

Cancer discovery·2026
Same author

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Cancer medicine·2026
Same author

Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction.

Expert opinion on pharmacotherapy·2026
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Essential thrombocythaemia (ET) diagnosis and management are evolving. New research offers clear guidance for high-risk ET patients and a powerful JAK2 mutation diagnostic tool for myeloproliferative disorders.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Essential thrombocythaemia (ET) is a myeloproliferative disorder with diagnostic challenges.
  • Optimal management of ET remains controversial due to limited randomized trials.

Purpose of the Study:

  • To provide updated guidance on managing high-risk essential thrombocythaemia.
  • To highlight the diagnostic and classificatory impact of the JAK2 mutation in myeloproliferative disorders.

Main Methods:

  • The Medical Research Council Primary Thrombocythaemia 1 (PT-1) trial, a large randomized study.
  • Identification and analysis of the JAK2 mutation in patients with essential thrombocythaemia and other myeloproliferative disorders.

Main Results:

Related Experiment Videos

  • The PT-1 trial provides clear management guidelines for high-risk essential thrombocythaemia.
  • The JAK2 mutation serves as a powerful diagnostic tool for essential thrombocythaemia and related disorders.

    • Conclusions:

    • Recent advancements, including the PT-1 trial and JAK2 mutation discovery, are transforming essential thrombocythaemia diagnosis and management.
    • These developments are expected to significantly alter the classification and treatment approaches for myeloproliferative disorders.